Palareti, Gualtiero 
ORCID: 0000-0002-4327-9561, Poli, Daniela, Ageno, Walter ORCID: 0000-0002-1922-8879, Legnani, Cristina ORCID: 0000-0003-1999-7800, Antonucci, Emilia, Bucherini, Eugenio, Testa, Sophie, Paoletti, Oriana, Chistolini, Antonio, Serrao, Alessandra ORCID: 0000-0002-3603-3598 et al (show 15 more authors)
(2022)
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study.
Blood advances, 6 (23).
pp. 6005-6015.
|
PDF
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism the Apidulcis study.pdf - Other Download (331kB) | Preview |
Abstract
D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE) for the risk of recurrence. However, this approach was never evaluated since direct oral anticoagulants are available. With this multicenter, prospective cohort study, we aimed to assess the value of an algorithm incorporating serial D-dimer testing and administration of reduced-dose apixaban (2.5 mg twice daily) only to patients with a positive test. A total of 732 outpatients aged 18 to 74 years, anticoagulated for ≥12 months after a first unprovoked VTE, were included. Patients underwent D-dimer testing with commercial assays and preestablished cutoffs. If the baseline D-dimer during anticoagulation was negative, anticoagulation was stopped and testing repeated after 15, 30, and 60 days. Patients with serially negative results (286 [39.1%]) were left without anticoagulation. At the first positive result, the remaining 446 patients (60.9%) were given apixaban for 18 months. All patients underwent follow-up planned for 18 months. The study was interrupted after a planned interim analysis for the high rate of primary outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2), including symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) recurrence, death for VTE, and major bleeding occurring in patients off anticoagulation vs that in those receiving apixaban (1.1%; 95% CI, 0.4-2.6; adjusted hazard ratio [HR], 8.2; 95% CI, 3.2-25.3). In conclusion, in patients anticoagulated for ≥1 year after a first unprovoked VTE, the decision to further extend anticoagulation should not be based on D-dimer testing. The results confirmed the high efficacy and safety of reduced-dose apixaban against recurrences. This trial was registered at www.clinicaltrials.gov as #NCT03678506.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Humans, Recurrence, Anticoagulants, Prospective Studies, Venous Thromboembolism |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 29 Feb 2024 11:44 |
| Last Modified: | 29 Feb 2024 11:44 |
| DOI: | 10.1182/bloodadvances.2022007973 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3179014 |
Dimensions
Dimensions
